I was just medling with medical archives to learn more about David Stamler.
He was the chief medical officer of Auspex which got bought by Teva for $3.5B. SD-809 was the lead candidate drug for treating chorea. The drug got FDA approval in 2017
This impeccable record could be the reason Stamler is paid a hefty salary. I will not be surprised if ATH434 walks in the footsteps of SD-809
I will wait until the end. I'm not releasing my shares.
Ann: Alterity Therapeutics Raises $4.8M AUD in Placement, page-24
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(11.1%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $14.25K | 2.930M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 66 | 81346070 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 19609447 | 23 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |